BioMarin and CAMP4 Collaborate on RNA-Targeting Therapies for Rare Genetic Diseases

Collaboration Agreement:
BioMarin Pharmaceutical Inc. and CAMP4 Therapeutics Corporation have entered into a strategic research collaboration to develop RNA-targeting medicines for rare genetic diseases.

Platform Utilization:
The collaboration leverages CAMP4’s RAP Platform, which identifies and characterizes RNA regulatory elements controlling gene expression, to develop novel therapeutic targets.

Target Selection:
BioMarin has the right to select two targets identified by CAMP4’s RAP Platform for further clinical development.

Financial Terms:
CAMP4 will receive an upfront payment and is eligible for additional milestone payments and tiered royalties based on the success of the collaboration.

Therapeutic Approach:
The collaboration aims to increase protein levels in patients with rare genetic diseases by targeting regulatory RNA sequences with antisense oligonucleotides (ASOs).

Strategic Impact:
The partnership strengthens BioMarin’s position in genetic medicines and expands CAMP4’s platform reach into additional therapeutic targets.

IPO Preparation:
CAMP4 is preparing for an initial public offering (IPO) while announcing this partnership.